Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease
Authors:
- Aya F. OzakiAOAya F. Ozaki
- Dennis T. KoDKDennis T. Ko
- Alice ChongACAlice Chong
- Jiming FangJFJiming Fang
- Clare L. AtzemaCAClare L. Atzema
- Peter C. AustinPAPeter C. Austin
- Therese A. StukelTSTherese A. Stukel
- Karen TuKTKaren Tu
- Jacob A. UdellJUJacob A. Udell
- David NaimarkDNDavid Naimark
- Gillian L. BoothGBGillian L. Booth
- Cynthia A. JackeviciusCJCynthia A. Jackevicius
Open Access
- 1 May 2023
- journal article
- research article
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 11 (3) , E494-E503
Abstract
Background Sodium–glucose cotransporter-2 (SGLT2) inhibitors are cardioprotective agents in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (CVD). Since little is known about their uptake in atherosclerotic CVD, we examined SGLT2 inhibitor prescribing trends and identified potential disparities in prescribing patterns. Methods We conducted an observational study using linked population-based health data in Ontario, Canada, from April 2016 to March 2020 of patients aged 65 years or older with concomitant type 2 diabetes and atherosclerotic CVD. To examine prevalent prescribing of SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin), we constructed 4 cross-sectional yearly cohorts from Apr. 1 to Mar. 31 (2016/17, 2017/18, 2018/19 and 2019/20). We estimated prevalent SGLT2 inhibitor prescribing by year and by subgroups, and identified factors associated with SGTL2 inhibitor prescribing using multivariable logistic regression. Results There were 208 303 patients in our overall cohort (median age 74.0 yr [interquartile range 68.0–80.0 yr], 132 196 [63.5%] male). Although SGLT2 inhibitor prescribing increased over time, from 7.0% to 20.1%, statin prescribing was initially 10-fold higher and later threefold higher than SGLT2 inhibitor prescribing. In 2019/20, SGLT2 inhibitor prescribing was roughly 50% lower among those aged 75 years or older than among those younger than 75 years (12.9% v. 28.3%, p < 0.001) and in women than in men (15.3% v. 22.9%, p < 0.001). Age 75 years or older, female sex, history of heart failure and kidney disease, and low income were independent factors of lower SGLT2 inhibitor prescribing. Among physician specialists, visits to endocrinologists and family physicians were stronger factors of SGLT2 inhibitor prescribing than cardiologist visits. Interpretation We found that 1 in 5 patients with diabetes and atherosclerotic CVD were prescribed SGLT2 inhibitors in 2019/20, whereas statins were prescribed for 4 of every 5 patients. Although SGLT2 inhibitor prescribing increased over the study period, disparities in adoption by age, sex, socioeconomic status, comorbidities and physician specialty remained.Keywords
This publication has 27 references indexed in Scilit:
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Identifying diabetes cases from administrative data: a population-based validation studyBMC Health Services Research, 2018
- Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational studyThe Lancet, 2018
- 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial InfarctionJACC, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- The Cardiovascular Health in Ambulatory Care Research Team (CANHEART)Circulation: Cardiovascular Quality and Outcomes, 2015
- Lipid-Lowering Therapy With Statins in High-Risk Elderly PatientsJAMA, 2004
- Model-Dependent Variance Inflation Factor Cutoff ValuesQuality Engineering, 2002
- Use of the Statins in Patients After Acute Myocardial InfarctionArchives of internal medicine (1960), 2001